Blog

Expert neuro-oncologist Santosh Kesari, MD, PhD, Director of Neuro-oncology at Pacific Neuroscience Institute and Chair and Professor of the Department of Translational Neurosciences at Saint John’s Cancer Institute, published the results from a phase 2 clinical trial for recurrent glioblastoma (rGBM), offering hope for improved survival outcomes and pushing novel treatment one step closer to FDA approval.

Santosh Kesari, MD, PhD, of Pacific Neuroscience Institute is the principal investigator for more than a dozen clinical trials, of which 8 are brain tumor-related. Dr. Kesari is Director of Neuro-oncology at PNI, and Chair and Professor of the Department of Translational Neurosciences at Saint John’s Cancer Institute. He is ranked among the top 1 percent of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd, and is an internationally recognized scientist and clinician.